Frontline immunotherapy and immune cold reprogramming across molecular subtypes of advanced endometrial cancer - PubMed
an hour ago
- #Endometrial Cancer
- #Immunotherapy
- #Precision Medicine
- Immunotherapy has become a frontline standard for dMMR/MSI-H advanced endometrial cancer, shifting treatment paradigms.
- For pMMR tumors (most cases), combination strategies like lenvatinib with immune checkpoint inhibitors are key to overcoming immune-cold resistance.
- Future directions include molecular monitoring through liquid biopsy and antibody-drug conjugates to further personalize immunotherapy.